PSMA PET/CT在复发性前列腺癌分期中的应用：是取景器，而非指南针。 - Suppr

Suppr

超能文献

PSMA PET/CT in staging recurrent prostate cancer: a viewfinder, not a compass.

作者信息

Bauckneht Matteo, Laudicella Riccardo, Lanfranchi Francesco, Ciccarese Chiara

机构信息

Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Department of Health Sciences (DISSAL), University of Genova, Genova, Italy.

出版信息

Eur Radiol. 2025 Jun;35(6):3131-3133. doi: 10.1007/s00330-024-11297-z. Epub 2024 Dec 18.

DOI:10.1007/s00330-024-11297-z

PMID:39694889

Abstract

摘要

相似文献

PSMA PET/CT in staging recurrent prostate cancer: a viewfinder, not a compass.PSMA PET/CT在复发性前列腺癌分期中的应用：是取景器，而非指南针。

Eur Radiol. 2025 Jun;35(6):3131-3133. doi: 10.1007/s00330-024-11297-z. Epub 2024 Dec 18.

The Role of 18F PSMA-1007 PET/CT in the Staging and Detection of Recurrence of Prostate Cancer, A Scoping Review.18F PSMA - 1007 PET/CT在前列腺癌分期及复发检测中的作用：一项范围综述

Cancers (Basel). 2025 Mar 20;17(6):1049. doi: 10.3390/cancers17061049.

Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Ga 标记前列腺特异性膜抗原配体正电子发射断层扫描/计算机断层扫描在前列腺癌中的应用：系统评价和荟萃分析。

Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.

Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.比较 68Ga-标记前列腺特异性膜抗原和 18F-胆碱 PET/CT 在前列腺癌分期/再分期中的表现：系统评价和荟萃分析。

Clin Nucl Med. 2019 May;44(5):365-376. doi: 10.1097/RLU.0000000000002526.

Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.前列腺癌中骨扫描和前列腺特异性膜抗原正电子发射断层扫描应用的五年趋势：私立中心的回顾性研究

J Med Imaging Radiat Oncol. 2019 Aug;63(4):495-499. doi: 10.1111/1754-9485.12885. Epub 2019 Apr 11.

Current status of theranostics in prostate cancer.前列腺癌治疗学的现状。

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):471-495. doi: 10.1007/s00259-017-3882-2. Epub 2017 Dec 28.

More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management.PSMA PET 扫描时代：前列腺癌管理中 PSMA PET 和淋巴结清扫的范式转变。

Semin Oncol Nurs. 2020 Aug;36(4):151044. doi: 10.1016/j.soncn.2020.151044. Epub 2020 Jul 25.

A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.一项前瞻性随机多中心研究，评估镓-68 前列腺特异性膜抗原（PSMA）PET/CT 成像在根治性手术或放疗前对高危前列腺癌分期的影响（proPSMA 研究）：临床试验方案。

BJU Int. 2018 Nov;122(5):783-793. doi: 10.1111/bju.14374. Epub 2018 Jun 3.

Risk of metastatic disease on gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.前列腺癌初诊时行镓-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描检查对 1253 例男性患者转移病灶的风险评估。

BJU Int. 2019 Sep;124(3):401-407. doi: 10.1111/bju.14828. Epub 2019 Jul 2.

引用本文的文献

Assessing the frequency and accuracy of morphologic changes of focal bone lesions on [Ga]Ga-PSMA-11 PET/CT in prostate cancer.评估[镓]Ga-PSMA-11 PET/CT对前列腺癌局灶性骨病变形态学变化的频率和准确性。

Eur J Nucl Med Mol Imaging. 2025 Jun 17. doi: 10.1007/s00259-025-07331-x.

本文引用的文献

Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).多种成像方法可能会影响接受转移灶定向治疗的寡转移性前列腺癌患者的长期肿瘤学结局（PRECISE-MDT研究）。

J Nucl Med. 2024 Aug 1;65(8):1202-1209. doi: 10.2967/jnumed.124.267586.

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.根治性放疗联合不同时长雄激素剥夺治疗前列腺癌的随机临床试验（RADICALS-HD）：长程与短程雄激素剥夺治疗的比较。

Lancet. 2024 Jun 1;403(10442):2416-2425. doi: 10.1016/S0140-6736(24)00549-X. Epub 2024 May 16.

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.EAU-EANM-ESTRO-ESUR-ISUP-SIOG 前列腺癌诊治指南。第二部分-2024 年更新：复发性和转移性前列腺癌的治疗。

Eur Urol. 2024 Aug;86(2):164-182. doi: 10.1016/j.eururo.2024.04.010. Epub 2024 Apr 29.

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.恩杂鲁胺治疗生化复发前列腺癌的疗效改善。

N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974.

Phase III Study of F-PSMA-1007 Versus F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study.F-PSMA-1007 与 F-氟代胆碱 PET/CT 用于前列腺癌生化复发定位的 III 期研究：一项前瞻性、随机、交叉多中心研究。

J Nucl Med. 2023 Apr;64(4):579-585. doi: 10.2967/jnumed.122.264743. Epub 2022 Nov 23.

Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer.将前列腺特异性膜抗原正电子发射断层扫描纳入新诊断或生化复发前列腺癌男性管理决策中。

Eur Urol. 2023 Jun;83(6):521-533. doi: 10.1016/j.eururo.2022.10.024. Epub 2022 Nov 18.

A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and Ga-PSMA-PET for biochemical relapse after radical prostatectomy - The PROPER 1 trial.一项关于前列腺特异性抗原引导下的挽救性放疗及镓-前列腺特异性膜抗原正电子发射断层扫描用于根治性前列腺切除术后生化复发的前瞻性II期研究——PROPER 1试验。

Clin Transl Radiat Oncol. 2022 Jul 5;36:77-82. doi: 10.1016/j.ctro.2022.07.001. eCollection 2022 Sep.

Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描与挽救性放疗治疗生化复发前列腺癌患者的肿瘤学结局改善相关。

Eur Urol Oncol. 2022 Apr;5(2):146-152. doi: 10.1016/j.euo.2022.01.001. Epub 2022 Jan 22.

F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.F-氟戊氨酸-PET/CT 成像与单独常规成像引导前列腺癌术后挽救性放疗的比较（EMPIRE-1）：一项单中心、开放标签、2/3 期随机对照临床试验。

Lancet. 2021 May 22;397(10288):1895-1904. doi: 10.1016/S0140-6736(21)00581-X. Epub 2021 May 7.

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with F-DCFPyL in Prostate Cancer Patients (OSPREY).前列腺特异性膜抗原 PET/CT 联合 F-DCFPyL 对前列腺癌患者的诊断准确性的 2/3 期前瞻性多中心研究（OSPREY）。

J Urol. 2021 Jul;206(1):52-61. doi: 10.1097/JU.0000000000001698. Epub 2021 Feb 26.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验